CN107320719A - Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途 - Google Patents

Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途 Download PDF

Info

Publication number
CN107320719A
CN107320719A CN201710596161.5A CN201710596161A CN107320719A CN 107320719 A CN107320719 A CN 107320719A CN 201710596161 A CN201710596161 A CN 201710596161A CN 107320719 A CN107320719 A CN 107320719A
Authority
CN
China
Prior art keywords
xten
hgh
sequence
fusion protein
bolus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201710596161.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·克莱兰
乔治·M·布莱特
埃里克·汉弗里斯
V·谢尔恩伯杰
J·西尔弗曼
W·P·施泰姆尔
王家威
N·吉西格
B·斯平克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Inc
Original Assignee
Amunix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Inc filed Critical Amunix Inc
Publication of CN107320719A publication Critical patent/CN107320719A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710596161.5A 2012-06-05 2013-03-14 Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途 Withdrawn CN107320719A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261689390P 2012-06-05 2012-06-05
US61/689,390 2012-06-05
US201261663475P 2012-06-22 2012-06-22
US61/663,475 2012-06-22
US201361763753P 2013-02-12 2013-02-12
US61/763,753 2013-02-12
CN201380041556.9A CN104519903A (zh) 2012-06-05 2013-03-14 Hgh-xten融合蛋白及其在治疗生长激素缺乏中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380041556.9A Division CN104519903A (zh) 2012-06-05 2013-03-14 Hgh-xten融合蛋白及其在治疗生长激素缺乏中的用途

Publications (1)

Publication Number Publication Date
CN107320719A true CN107320719A (zh) 2017-11-07

Family

ID=47998551

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710596161.5A Withdrawn CN107320719A (zh) 2012-06-05 2013-03-14 Hgh‑xten融合蛋白及其在治疗生长激素缺乏中的用途
CN201380041556.9A Pending CN104519903A (zh) 2012-06-05 2013-03-14 Hgh-xten融合蛋白及其在治疗生长激素缺乏中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380041556.9A Pending CN104519903A (zh) 2012-06-05 2013-03-14 Hgh-xten融合蛋白及其在治疗生长激素缺乏中的用途

Country Status (17)

Country Link
US (2) US20140162949A1 (enExample)
EP (1) EP2858664B1 (enExample)
JP (2) JP2015520188A (enExample)
KR (1) KR20150021072A (enExample)
CN (2) CN107320719A (enExample)
AU (1) AU2013272220A1 (enExample)
BR (1) BR112014030404A2 (enExample)
CA (1) CA2875827A1 (enExample)
DK (1) DK2858664T3 (enExample)
ES (1) ES2733220T3 (enExample)
HK (1) HK1208629A1 (enExample)
IL (1) IL236070A0 (enExample)
MX (1) MX2014014927A (enExample)
NZ (1) NZ702557A (enExample)
PH (1) PH12014502738A1 (enExample)
SG (1) SG11201408152VA (enExample)
WO (1) WO2013184216A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554343A (zh) * 2022-01-30 2023-08-08 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2014164568A1 (en) * 2013-03-11 2014-10-09 Amunix Operating Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
EP3416677B1 (en) 2016-02-17 2022-08-03 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
WO2018022939A1 (en) * 2016-07-27 2018-02-01 Amunix Operating Inc. Treatment of adult growth hormone deficiency with human growth hormone analogues
CN118105512A (zh) 2016-08-30 2024-05-31 株式会社吉耐森 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR20260039804A (ko) 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN116003632B (zh) * 2022-12-07 2026-02-24 北京大学 长效缓释型人重组生长激素融合蛋白及其药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
PE20121539A1 (es) * 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFFREY L. CLELAND ET AL.: "A Novel Human Growth Hormone XTEN Construct (VRS‐317) for Monthly Administration", 《ENDOCRINE JOURNAL》 *
JL CLELAND ET AL.: "A Novel Human Growth Hormone XTEN Construct (VRS-317) for Once-a-Month Subcutaneous Administration in a Phase 1a Study of Growth Hormone-Deficient Adults", 《ENDOCR REV》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554343A (zh) * 2022-01-30 2023-08-08 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用

Also Published As

Publication number Publication date
JP2017125051A (ja) 2017-07-20
BR112014030404A2 (pt) 2017-06-27
PH12014502738A1 (en) 2015-02-02
ES2733220T3 (es) 2019-11-28
JP2015520188A (ja) 2015-07-16
US20140162949A1 (en) 2014-06-12
HK1208629A1 (en) 2016-03-11
KR20150021072A (ko) 2015-02-27
SG11201408152VA (en) 2015-01-29
EP2858664B1 (en) 2019-05-08
MX2014014927A (es) 2015-05-15
AU2013272220A1 (en) 2015-01-15
IL236070A0 (en) 2015-01-29
CA2875827A1 (en) 2013-12-12
NZ702557A (en) 2017-06-30
EP2858664A1 (en) 2015-04-15
WO2013184216A1 (en) 2013-12-12
US20180051063A1 (en) 2018-02-22
DK2858664T3 (da) 2019-07-08
CN104519903A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
EP2858664B1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
JP6704358B2 (ja) 代謝障害を治療するための組成物および使用方法
JP2019056013A (ja) ヒト成長ホルモン類似体を用いた小児成長ホルモン分泌不全症の治療
CN102119033B (zh) 用于增强促生长素抑制素免疫原性的组合物和方法
JP2022068275A (ja) Ｆｇｆ２１変異体
EA030619B1 (ru) Гибридный белок, включающий последовательности гормона роста и xten, способ его получения и применения
US20170182122A1 (en) Methods and compositions for the treatment of metabolic disorders and diseases
CN107080835A (zh) 长效生长激素及其生产方法
SA519410598B1 (ar) طريقة علاج أو تخفيف الاضطرابات الأيضية باستخدام بروتينات الربط لمستقبل ببتيد التثبيط المعوي في توليفة مع مساعدات بولي بيبتيدات شبيه بالجلوكاجون-1
EP4159758A1 (en) Rhfgf21 fusion protein, polynucleotide encoding rhfgf21 fusion protein, composition containing rhfgf21 fusion protein, and use of rhfgf21 fusion protein
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
WO2016109823A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
EP3500284A1 (en) Bovine fibroblast growth factor 21 and ketosis in dairy cattle
US20200000884A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
US20220362359A1 (en) Dna vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
HK1237790B (en) Compositions and methods of use for treating metabolic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20171107

WW01 Invention patent application withdrawn after publication